Collegium Pharmaceutical Q2 2024 Adj. EPS $1.62 Beats $1.51 Estimate, Sales $145.300M Beat $143.938M Estimate
Portfolio Pulse from Benzinga Newsdesk
Collegium Pharmaceutical (NASDAQ: COLL) reported Q2 2024 adjusted EPS of $1.62, beating the estimate of $1.51. Sales were $145.3M, surpassing the $143.938M estimate and showing a 7.20% increase from the same period last year.
August 08, 2024 | 8:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Collegium Pharmaceutical reported strong Q2 2024 earnings with an adjusted EPS of $1.62, beating estimates by 7.28%. Sales also surpassed expectations, reaching $145.3M, a 7.20% increase YoY.
The company's better-than-expected earnings and sales figures are likely to positively impact the stock price in the short term. Beating both EPS and sales estimates indicates strong performance and growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100